Minocycline as a potential therapeutic agent in neurodegenerative disorders characterised by protein misfolding

Prion

Volumn 3, Issue 2, 2009, Pages 78-83

  Noble, Wendy ^a   Garwood, Claire J ^a   Hanger, Diane P ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Minocycline; Neurodegeneration; Neuroinflammation; Protein aggregation; Protein misfolding

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; CASPASE; CYCLOOXYGENASE 2; HUNTINGTIN; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 1BETA; INTERLEUKIN 2; MATRIX METALLOPROTEINASE; MINOCYCLINE; PROTEIN KINASE; TUMOR NECROSIS FACTOR ALPHA; UBIDECARENONE;

ALZHEIMER DISEASE; ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; ASTROCYTOSIS; CHELATION; DEGENERATIVE DISEASE; ENZYME ACTIVATION; GLIOSIS; HUMAN; HUNTINGTON CHOREA; INFLAMMATION; MOTOR NEURON DISEASE; NERVE CELL NECROSIS; NEUROGENIC INFLAMMATION; NEUROPROTECTION; NONHUMAN; NOTE; PARKINSON DISEASE; PATHOGENESIS; PRION DISEASE; PROTEIN AGGREGATION; PROTEIN CLEAVAGE; PROTEIN CONFORMATION; PROTEIN DEGRADATION; PROTEIN FOLDING; PROTEIN PHOSPHORYLATION; TAUOPATHY;

ANIMALS; ANTI-BACTERIAL AGENTS; HUMANS; MINOCYCLINE; MOLECULAR STRUCTURE; NEURODEGENERATIVE DISEASES; PROTEIN FOLDING;

EID: 70349573768     PISSN: 19336896     EISSN: 1933690X     Source Type: Journal    
DOI: 10.4161/pri.3.2.8820     Document Type: Note

References (74)

1. Dohm CP, Kermer P, Bahr M. Aggregopathy in neurodegenerative diseases: mechanisms and therapeutic implications. Neurodegen Dis 2008; 5:1-3.
2. Moore RA, Taubner LM, Priola S. Prion protein misfolding and disease. Curr Opin Struct Biol 2009; 19:1-9.
3. Soto C, Estrada LD. Protein misfolding and neurodegeneration. Arch Neurol 2008; 65:184-189 (Pubitemid 351240778)
4. Skaper SD. The brain as a target for inflammatory processes and neuroprotective strategies. Ann N Y Acad Sci 2007; 1122:23-34. (Pubitemid 350249539)
5. Bredesen DE. Programmed cell death mechanisms in neurological disease. Curr Mol Med 2008; 8:173-186
6. Stirling DP, Koochesfahani KM, Steeves JD, Tetzlaff W. Minocycline as a neuroprotective agent. Neuroscientist 2005; 11:308-322 (Pubitemid 41040860)
7. http://en.wikipedia.org/wiki/Minocycline.
8. Yrjanheikki J, Keinanen R, Pellikka M, Hokfelt T, Koistinaho J. Tetracyclines inhibit microglial activation and are neuroprotective in global brain ischemia. Proc Natl Acad Sci USA 1998; 95:15769-15774 (Pubitemid 29018775)
9. Noble W, Garwood C, Stephenson J, Kinsey AM, Hanger DP, Anderton BH. Minocycline reduces the development of abnormal tau species in models of Alzheimer's disease. FASEB J 2009; 23:739-750
10. Stirling DP, Koochesfahani KM, Steeves JD, Tetzlaff W. Minocycline as a neuroprotective agent. Neuroscientist 2005; 11:308-322 (Pubitemid 41040860)
11. De LA, Colombo L, Diomede L, Capobianco R, Mangieri M, Miccolo C, et al. The efficacy of tetracyclines in peripheral and intracerebral prion infection. PLoS ONE 2008; 3:1888. (Pubitemid 351943730)
12. Alano CC, Kauppinen TM, Valls AV, Swanson RA. Minocycline inhibits poly(ADPribose) polymerase-1 at nanomolar concentrations. Proc Natl Acad Sci USA 2006; 103:9685-9690 (Pubitemid 43955885)
13. Tikka TM, Koistinaho JE. Minocycline provides neuroprotection against N-methyl-Daspartate neurotoxicity by inhibiting microglia. J Immunol 2001; 166:7527-7533 (Pubitemid 32525632)
14. Ryu JK, Choi HB, McLarnon JG. Combined minocycline plus pyruvate treatment enhances effects of each agent to inhibit inflammation, oxidative damage, and neuronal loss in an excitotoxic animal model of Huntington's disease. Neuroscience 2006; 141:1835-1848 (Pubitemid 44233147)
15. Lin S, Wei X, Xu Y, Yan C, Dodel R, Zhang Y, et al. Minocycline blocks 6-hydroxydopamine- induced neurotoxicity and free radical production in rat cerebellar granule neurons. Life Sci 2003; 72:1635-1641 (Pubitemid 36120789)
16. Familian A, Boshuizen RS, Eikelenboom P, Veerhuis R. Inhibitory effect of minocycline on amyloid beta fibril formation and human microglial activation. Glia 2006; 53:233-240 (Pubitemid 43221345)
17. Chen M, Ona VO, Li M, Ferrante RJ, Fink KB, Zhu S, et al. Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington disease. Nat Med 2000; 6:797-801. (Pubitemid 30469429)
18. Hanger DP, Anderton BH, Noble W. Tau phosphorylation: the therapeutic challenge for neurodegenerative disease. Trends Mol Med 2009; EPub ahead of print.
19. Small SA, Duff K. Linking Abeta and tau in late-onset Alzheimer's disease: a dual pathway hypothesis. Neuron 2008; 60:534-542
20. Anderson JP, Walker DE, Goldstein JM, de LR, Banducci K, Caccavello RJ, et al. Phosphorylation of Ser-129 is the dominant pathological modification of alpha-synuclein in familial and sporadic Lewy body disease. J Biol Chem 2006; 281:29739-29752 (Pubitemid 44536983)
21. Tan JM, Wong ES, Lim KL. Protein Misfolding and Aggregation in Parkinson Disease. Antioxid Redox Signal 2009; EPub ahead of print.
22. Yang YX, Wood NW, Latchman DS. Molecular basis of Parkinson's disease. Neuroreport 2009; 20:150-156
23. DiFiglia M, Sapp E, Chase KO, Davies SW, Bates GP, Vonsattel JP, Aronin N. Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. Science 1997; 277:1990-1993 (Pubitemid 27449140)
24. Bruijn LI, Houseweart MK, Kato S, Anderson KL, Anderson SD, Ohama E, et al. Aggregation and motor neuron toxicity of an ALS-linked SOD1 mutant independent from wild-type SOD1. Science 1998; 281:1851-1854 (Pubitemid 28450505)
25. Moore RA, Taubner LM, Priola SA. Prion protein misfolding and disease. Curr Opin Struct Biol 2009; 19:14-22.
26. Forloni G, Iussich S, Awan T, Colombo L, Angeretti N, Girola L, et al. Tetracyclines affect prion infectivity. Proc Natl Acad Sci USA 2002; 99:10849-10854 (Pubitemid 34907065)
27. Tagliavini F, Forloni G, Colombo L, Rossi G, Girola L, Canciani B, et al. Tetracycline affects abnormal properties of synthetic PrP peptides and PrP(Sc) in vitro. J Mol Biol 2000; 300:1309-1322 (Pubitemid 30695610)
28. Laurén J, Gimbel DA, Nygaard HB, Gilbert JW, Strittmatter SM. Cellular prion protein mediates impairment of synaptic plasticity by amyloid-beta oligomers. Nature 2009; 457:1128-1132
29. Andorfer C, Kress Y, Espinoza M, de SR, Tucker KL, Barde YA, et al. Hyperphosphorylation and aggregation of tau in mice expressing normal human tau isoforms. J Neurochem 2003; 86:582-590 (Pubitemid 36897439)
30. Smith DL, Woodman B, Mahal A, Sathasivam K, Ghazi-Noori S, Lowden PA, et al. Minocycline and doxycycline are not beneficial in a model of Huntington's disease. Ann Neurol 2003; 54:186-196 (Pubitemid 36909617)
31. Mievis S, Levivier M, Communi D, Vassart G, Brotchi J, Ledent C, Blum D. Lack of minocycline efficiency in genetic models of Huntington's disease. Neuromolecular Med 2007; 9:47-54. (Pubitemid 44772275)
32. Stack EC, Smith KM, Ryu H, Cormier K, Chen M, Hagerty SW, et al. Combination therapy using minocycline and coenzyme Q10 in R6/2 transgenic Huntington's disease mice. Biochim Biophys Acta 2006; 1762:373-380 (Pubitemid 43172854)
33. Blum D, Chtarto A, Tenenbaum L, Brotchi J, Levivier M. Clinical potential of minocycline for neurodegenerative disorders. Neurobiol Dis 2004; 17:359-366 (Pubitemid 39574870)
34. Lambert MP, Barlow AK, Chromy BA, Edwards C, Freed R, Liosatos M, et al. Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins. Proc Natl Acad Sci USA 1998; 95:6448-6453 (Pubitemid 28249033)
35. Novitskaya V, Bocharova OV, Bronstein I, Baskakov IV. Amyloid fibrils of mammalian prion protein are highly toxic to cultured cells and primary neurons. J Biol Chem 2006; 281:13828-13836 (Pubitemid 43855298)
36. Lichtlen P, Mohajeri MH. Antibody-based approaches in Alzheimer's research: safety, pharmacokinetics, metabolism, and analytical tools. J Neurochem 2008; 104:859-874 (Pubitemid 351143651)
37. Resende R, Ferreiro E, Pereira C, Resende de OC. Neurotoxic effect of oligomeric and fibrillar species of amyloid-beta peptide 1-42: involvement of endoplasmic reticulum calcium release in oligomer-induced cell death. Neuroscience 2008; 155:725-737
38. Kloppenburg M, Verweij CL, Miltenburg AM, Verhoeven AJ, Daha MR, Dijkmans BA, Breedveld FC. The influence of tetracyclines on T cell activation. Clin Exp Immunol 1995; 102:635-641 (Pubitemid 26013229)
39. Amin AR, Attur MG, Thakker GD, Patel PD, Vyas PR, Patel RN, et al. A novel mechanism of action of tetracyclines: effects on nitric oxide synthases. Proc Natl Acad Sci USA 1996; 93:14014-14019 (Pubitemid 26424237)
40. Brundula V, Rewcastle NB, Metz LM, Bernard CC, Yong VW. Targeting leukocyte MMPs and transmigration: minocycline as a potential therapy for multiple sclerosis. Brain 2002; 125:1297-1308 (Pubitemid 34587139)
41. Follstaedt SC, Barber SA, Zink MC. Mechanisms of minocycline-induced suppression of simian immunodeficiency virus encephalitis: inhibition of apoptosis signal-regulating kinase 1. J Neurovirol 2008; 14:376-388 (Pubitemid 352762877)
42. 2-induced cell death via JNK and p38 MAPK pathways. Int J Mol Med 2008; 22:9-16.
43. Bosco A, Inman DM, Steele MR, Wu G, Soto I, Marsh-Armstrong N, et al. Reduced retina microglial activation and improved optic nerve integrity with minocycline treatment in the DBA/2J mouse model of glaucoma. Invest Ophthalmol Vis Sci 2008; 49:1437-1446
44. Wu DC, Jackson-Lewis V, Vila M, Tieu K, Teismann P, Vadseth C, et al. Blockade of microglial activation is neuroprotective in the 1-methyl-4-phenyl-1, 2,3,6-tetrahydropyridine mouse model of Parkinson disease. J Neurosci 2002; 22:1763-1771
45. Casarejos MJ, Menendez J, Solano RM, Rodriguez-Navarro JA, Garcia de YJ, Mena MA. Susceptibility to rotenone is increased in neurons from parkin null mice and is reduced by minocycline. J Neurochem 2006; 97:934-946
46. Purisai MG, McCormack AL, Cumine S, Li J, Isla MZ, Di Monte DA. Microglial activation as a priming event leading to paraquat-induced dopaminergic cell degeneration. Neurobiol Dis 2007; 25:392-400. (Pubitemid 46124019)
47. Van Den BL, Tilkin P, Lemmens G, Robberecht W. Minocycline delays disease onset and mortality in a transgenic model of ALS. Neuroreport 2002; 13:1067-1070 (Pubitemid 34587742)
48. Kriz J, Nguyen MD, Julien JP. Minocycline slows disease progression in a mouse model of amyotrophic lateral sclerosis. Neurobiol Dis 2002; 10:268-278 (Pubitemid 35217580)
49. Seabrook TJ, Jiang L, Maier M, Lemere CA. Minocycline affects microglia activation, Abeta deposition, and behavior in APP-tg mice. Glia 2006; 53:776-782
50. Reyes JF, Reynolds MR, Horowitz PM, Fu Y, Guillozet-Bongaarts AL, Berry R, Binder LI. A possible link between astrocyte activation and tau nitration in Alzheimer's disease. Neurobiol Dis 2008; 31:198-208.
51. Garwood CJ, Anderton BH, Hanger DP and Noble W. Minocycline reduces caspase-3 activation and prevents cleavage and aggregation of tau in vivo. Alzheimer's and Dementia 2008; 484:2-381.
52. Sim RB, Kishore U, Villiers CL, Marche PN, Mitchell DA. C1q binding and complement activation by prions and amyloids. Immunobiology 2007; 212:355-362 (Pubitemid 46825245)
53. Veerhuis R, Van Breemen MJ, Hoozemans JM, Morbin M, Ouladhadj J, Tagliavini F, Eikelenboom P. Amyloid beta plaque-associated proteins C1q and SAP enhance the Abeta1-42 peptide-induced cytokine secretion by adult human microglia in vitro. Acta Neuropathol 2003; 105:135-144 (Pubitemid 36798799)
54. Hetz C, Russelakis-Carneiro M, Maundrell K, Castilla J, Soto C. Caspase-12 and endoplasmic reticulum stress mediate neurotoxicity of pathological prion protein. EMBO J 2003; 22:5435-5445 (Pubitemid 37279953)
55. Okouchi M, Ekshyyan O, Maracine M, Aw TY. Neuronal apoptosis in neurodegeneration. Antioxid Redox Signal 2007; 9:1059-1096 (Pubitemid 47080820)
56. Checler F, Vincent B. Alzheimer's and prion diseases: distinct pathologies, common proteolytic denominators. Trends Neurosci 2002; 25:616-620 (Pubitemid 35356508)
57. Rambold AS, Miesbauer M, Rapaport D, Bartke T, Baier M, Winklhofer KF, Tatzelt J. Association of Bcl-2 with misfolded prion protein is linked to the toxic potential of cytosolic PrP. Mol Biol Cell 2006; 17:3356-3368 (Pubitemid 44156431)
58. Ona VO, Li M, Vonsattel JP, Andrews LJ, Khan SQ, Chung WM, et al. Inhibition of caspase-1 slows disease progression in a mouse model of Huntington's disease. Nature 1999; 399:263-267 (Pubitemid 29246456)
59. Pasinelli P, Borchelt DR, Houseweart MK, Cleveland DW, Brown RH Jr. Caspase-1 is activated in neural cells and tissue with amyotrophic lateral sclerosis-associated mutations in copper-zinc superoxide dismutase. Proc Natl Acad Sci USA 1998; 95:15763-15768 (Pubitemid 29018774)
60. Ho CC, Rideout HJ, Ribe E, Troy CM, Dauer WT. The Parkinson disease protein leucine-rich repeat kinase 2 transduces death signals via Fas-associated protein with death domain and caspase-8 in a cellular model of neurodegeneration. J Neurosci 2009; 29:1011-1016
61. Anantharam V, Kitazawa M, Latchoumycandane C, Kanthasamy A, Kanthasamy AG. Blockade of PKCdelta proteolytic activation by loss of function mutants rescues mesencephalic dopaminergic neurons from methylcyclopentadienyl manganese tricarbonyl (MMT)-induced apoptotic cell death. Ann NY Acad Sci 2004; 1035:271-289 (Pubitemid 40362339)
62. Zhu S, Stavrovskaya IG, Drozda M, Kim BY, Ona V, Li M, et al. Minocycline inhibits cytochrome c release and delays progression of amyotrophic lateral sclerosis in mice. Nature 2002; 417:74-78
63. Chu HC, Lin YL, Sytwu HK, Lin SH, Liao CL, Chao YC. Effects of minocycline on Fas-mediated fulminant hepatitis in mice. Br J Pharmacol 2005; 144:275-282 (Pubitemid 40216125)
64. Haroon MF, Fatima A, Scholer S, Gieseler A, Horn TF, Kirches E, et al. Minocycline, a possible neuroprotective agent in Leber's hereditary optic neuropathy (LHON): studies of cybrid cells bearing 11,778 mutation. Neurobiol Dis 2007; 28:237-250 (Pubitemid 350116596)
65. Wang X, Zhu S, Drozda M, Zhang W, Stavrovskaya IG, Cattaneo E, et al. Minocycline inhibits caspase-independent and -dependent mitochondrial cell death pathways in models of Huntington's disease. Proc Natl Acad Sci USA 2003; 100:10483-10487 (Pubitemid 37071904)
66. Guillozet-Bongaarts AL, Garcia-Sierra F, Reynolds MR, Horowitz PM, Fu Y, Wang T, et al. Tau truncation during neurofibrillary tangle evolution in Alzheimer's disease. Neurobiol Aging 2005; 26:1015-1022 (Pubitemid 40312665)
67. Binder LI, Guillozet-Bongaarts AL, Garcia-Sierra F, Berry RW. Tau, tangles and Alzheimer's disease. Biochim Biophys Acta 2005; 1739:216-223 (Pubitemid 40018540)
68. Holmberg CI, Staniszewski KE, Mensah KN, Matouschek A, Morimoto RI. Inefficient degradation of truncated polyglutamine proteins by the proteasome. EMBO J 2004; 23:4307-4318 (Pubitemid 39546168)
69. Kahns S, Lykkebo S, Jakobsen LD, Nielsen MS, Jensen PH. Caspase-mediated parkin cleavage in apoptotic cell death. J Biol Chem 2002; 277:15303-15308 (Pubitemid 34967791)
70. Leigh PN, Meininger V, Bensimon G, Cudkowicz M, Robberecht W. Minocycline for patients with ALS. Lancet Neurol 2008; 7:119-120
71. Diguet E, Fernagut PO, Wei X, Du Y, Rouland R, Gross C, et al. Deleterious effects of minocycline in animal models of Parkinson's disease and Huntington's disease. Eur J Neurosci 2004; 19:3266-3276 (Pubitemid 38859544)
72. Fernandez-Gomez FJ, Gomez-Lazaro M, Pastor D, Calvo S, Aguirre N, Galindo MF, Jordan J. Minocycline fails to protect cerebellar granular cell cultures against malonateinduced cell death. Neurobiol Dis 2005; 20:384-391 (Pubitemid 41476264)
73. Saganova K, Orendacova J, Cizkova D, Vanicky I. Limited minocycline neuroprotection after balloon-compression spinal cord injury in the rat. Neurosci Lett 2008; 433:246-249
74. Stefanova N, Mitschnigg M, Ghorayeb I, Diguet E, Geser F, Tison F, et al. Failure of neuronal protection by inhibition of glial activation in a rat model of striatonigral degeneration. J Neurosci Res 2004; 78:87-91. (Pubitemid 39305157)